Jco precision oncology.

JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …DOI: 10.1200/PO.21.00510 JCO Precision Oncology no. 6 (2022) e2100510. Published online June 8, 2022. PMID: 35675577. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures Kabir Mody, MD 1. x. Kabir Mody. Search for articles by this author; ...Web20 Oct 2022 ... JCO Precision Oncology. Source Reference: opens in a new tab or windowHubbeling H, et al "Outcomes with local therapy and tyrosine kinase ...DOI: 10.1200/PO.22.00621 JCO Precision Oncology no. 7 (2023) e2200621. Published online February 21, 2023. Published online February 21, 2023. Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS G12C -Mutant Non–Small-Cell Lung Cancer

DOI: 10.1200/PO.18.00383 JCO Precision Oncology - published online August 16, 2019 Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D–CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study Julio Peguero, MD 1. x. Julio Peguero. Search for articles by this author ...Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ... DOI: 10.1200/PO.20.00494 JCO Precision Oncology no. 5 (2021) 1325-1338. Published online August 25, 2021. Published online August 25, 2021. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...

Jan 27, 2022 · This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech DOI: 10.1200/PO.20.00429 JCO Precision Oncology no. 5 (2021) 1001-1012. Published online June 10, 2021. PMID: 34994626. Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model Eryn Dow, BSc, BMBS 1, 2. x. Eryn Dow. Search for articles by this …The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...DOI: 10.1200/PO.21.00283 JCO Precision Oncology no. 6 (2022) e2100283. Published online May 25, 2022. PMID: 35613412. Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion Anne Thorwarth, MD 1. x. Anne Thorwarth ...DOI: 10.1200/PO.20.00504 JCO Precision Oncology no. 6 (2022) e2000504. Published online January 27, 2022. PMID: 35085008. Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing Jayne Y. Hehir-Kwa, PhD 1. x. Jayne Y. Hehir-Kwa. Search for articles by this author ...

Aug 5, 2021 · DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

DOI: 10.1200/PO.19.00297 JCO Precision Oncology no. 4 (2020) 170-175. Published online March 6, 2020. Published online March 6, 2020. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages

DOI: 10.1200/PO.21.00210 JCO Precision Oncology no. 5 (2021) 1530-1539. Published online September 29, 2021. Published online September 29, 2021. Molecular Tumor Board Review and Improved Overall Survival in …WebDOI: 10.1200/PO.22.00715 JCO Precision Oncology no. 7 (2023) e2200715. Published online June 7, 2023. PMID: 37285561. Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer Sarah N. Gibbs, MPH 1. x. Sarah N. Gibbs. Search for articles by this author ...WebOncoTree is also used by OncoKB, 27 a precision oncology knowledge base containing information about the biological effects and clinical implications of genomic alterations in cancer. 28 OncoKB uses the OncoTree classifications in conjunction with genomic information (gene and alterations) to annotate therapeutic, prognostic, and …CHASTEPA metro station (2nd station), SCHOOL #303. A reliable partner for everyone who cares about their health. We offer a wide range of services, ranging from laboratory and …DOI: 10.1200/PO.21.00210 JCO Precision Oncology no. 5 (2021) 1530-1539. Published online September 29, 2021. Published online September 29, 2021. Molecular Tumor Board Review and Improved Overall Survival in …WebDOI: 10.1200/PO.19.00399 JCO Precision Oncology no. 4 (2020) 370-381. Published online April 21, 2020. PMID: 32462107Limit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible.

Most patients are diagnosed with early-stage breast cancer (EBC), which is potentially curable with standard treatments. 3 Although (neo)adjuvant chemotherapies (NAC) reduce the risk of recurrence and death, approximately 30% of patients with EBC will experience recurrence in the first 10 years after surgery. 4 Recent studies have reported that circulating tumor DNA (ctDNA) detection in ...DOI: 10.1200/PO.21.00122 JCO Precision Oncology no. 5 (2021) 1354-1376. Published online August 25, 2021. Published online August 25, 2021. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsPURPOSE DNA polymerase epsilon is critical to DNA proofreading and replication. Mutations in POLE have been associated with hypermutated tumors and antitumor response to immune checkpoint inhibitor (ICI) therapy. We present a clinicopathologic analysis of patients with advanced cancers harboring POLE mutations, the pattern of co-occurring mutations, and their response to ICI therapy within the ...For this reason, JCO Precision Oncology has organized this special series of tutorial and review articles on statistical methods for precision oncology that will serve as a bridge between the clinical researcher and statistician communities, will help facilitate the application of new methods, and will stimulate the development of more and ...Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportDOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...

Drug-related pneumonitis as a result of novel cancer therapy provides new challenges for providers of cancer care in the era of precision medicine. Awareness of this emerging entity and knowledge of its manifestations and management guidelines are essential for state-of-the-art practice of clinical oncology. Here, we provide a detailed …DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportWeb

Final Summary · The impact factor of JCO Precision Oncology is 5.479. · The JCO Precision Oncology is a reputed research journal. · It is published by ...PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ...Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO PostJCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...Regrettably, the proportion of patients with advanced cancer outstrip the specialty PC workforce capacity. 20 In the United States, there are currently about 1,700-3,300 full-time equivalents of board-certified PC specialists, most of whom are not oncology-specific, and care for patients with other serious illness. 21,22 Unfortunately, the current pipeline for future PC physicians is narrow ...DOI: 10.1200/PO.21.00245 JCO Precision Oncology no. 6 (2022) e2100245. Published online March 23, 2022. PMID: 35319967. Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers Mohamed E. Salem, MD 1. x ...WebKey Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...JCO Precision Oncology Conversations is a monthly podcast featuring conversations with authors of clinically relevant and significant articles published in the …DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...

DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportWeb

Mar 9, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines

JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer.JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed to provide the best quality. The journal welcomes submissions from the research community where emphasis will be placed on the originality and the practical impact of the reported research.Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …Limit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared.Oct 6, 2022 · DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714 DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ...A precision haircut is a style using techniques that create straight, dramatic lines and clean angles. Vidal Sassoon was the pioneer of precision haircutting, with the original philosophy of creating haircuts based on a client’s bone struct...JCO Precis Oncol. 2017; 1: ... To address these limitations, we describe OncoKB, a comprehensive precision oncology knowledge base that offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors to support optimal treatment decisions. OncoKB …JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebDOI: 10.1200/JCO.23.01881 Journal of Clinical Oncology - published online before print December 4, 2023 ... Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO …

DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...PURPOSE The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population ...DOI: 10.1200/PO.19.00032 JCO Precision Oncology - published online October 24, 2019Instagram:https://instagram. this weeks stock marketjetzero stock symbolvital energy stockstock premarket movers JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not … qqq newsbest pet insurance in california This is the context motivating the publication by Stetson et al 10 in JCO Precision Oncology. The authors sent aliquots of plasma to four commercial Clinical Laboratory Improvement Amendments–certified laboratories for plasma NGS and compared this to NGS performed on matched tumor and normal tissue at Foundation Medicine. …In prior studies, 10% to 15% of MSI/dMMR colorectal cancer cases and 10% of MSI/dMMR endometrial cancer cases were caused by Lynch syndrome. 21,22,29 Lynch syndrome can increase the risk of many of the malignancies found to be MSI in the studies presented in JCO Precision Oncology; thus it is important for physicians to refer … mint mobile stock Nov 17, 2021 · Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ... PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ...